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Background: Tumor-induced lymphangiogenesis is a crucial step in malignant invasion and metastasis. Extracellular
matrix protein 1 (ECM1) was recently reported to play a role in lymphangiogenesis. In the present work, we aimed
to evaluate the role of ECM1 in gastric cancer and examined whether aberrant expression of ECM1 increased the
tumorigenic and metastatic potential of human gastric cancer.
Methods: The mRNA and protein expression of ECM1 in gastric cancer specimen and the noncancerous
counterparts from 77 patients were detected by real-time PCR and immunohistochemistry staining. Lymphatic
microvessel density (LMVD) in the corresponding serial sections was assessed by counting the lymphatic microvessels
labelled by D2-40. The correlations between ECM1 expression, LMVD, and the clinicopathological parameters were
examined.
Results: ECM1 protein expression was detected in 70.1% (54/77) of gastric cancer specimen, significantly higher
than that in the corresponding counterparts (P <0.01). ECM1 mRNA in tumor specimen was also dramatically
amplified. Elevated LMVD and ECM1 were positively correlated (P <0.01). In addition, ECM1 protein expression was
also closely associated with depth of tumor invasion and TNM stage (P <0.05, respectively).
Conclusions: ECM1 expression is aberrant elevated in tumor specimen and is closely related to the tumorigenic
and metastatic potential of human gastric cancer. Thus, carrying out the protein examination may be beneficial to
predict carcinogenesis and metastatic spread of human gastric cancer.
Keywords: Extracellular matrix protein 1 (ECM1), Lymphatic microvessel density (LMVD), Gastric cancer, Real-time
PCR (RT-PCR), ImmunohistochemistryBackground
Tumor metastasis is the main leading cause of cancer-
related death in patients with gastric cancer. Lymph node
metastasis is the hallmark of tumor progression and is con-
sidered as one of the most important prognostic factors.
Currently, no effective treatment modalities are available
for this progression. Tumor-induced lymphangiogenesis
is a crucial step for tumor progression and has been
demonstrated to be prior to the onset of lymphatic invasion
and metastasis [1-3]. Furthermore, increasing number
of lymphatic microvessels provides more opportunities* Correspondence: youjunxm@163.com; zhangzhiming164@aliyun.com
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unless otherwise stated.for tumor cells to disseminate to the lymphatic system
[4,5]. Nowadays, lymphangiogenesis is quantified by
lymphatic microvessel density (LMVD) for convenience,
which is applied to evaluate the status of lymphangio-
genesis and the remodeling or regression of lymphatic
vessels [6-8].
Extracellular matrix protein 1 (ECM1) is a soluble pro-
tein, which was first identified in 1994 [9]. Mutations in
this gene were reported to be associated with lipoid pro-
teinosis disorder (known as hyalinosis cutis et mucosae or
Urbach-Wiethe disease), which is characterized by gener-
alized thickening of skin, mucosa, and certain viscera [10].
Recent study revealed that a homozygous frameshift mu-
tation in ECM1 led to a failure of human mucocutaneous
lymphangiogenesis [11], suggesting the role of this gene in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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highly purified recombinant ECM1 stimulated prolifera-
tion of cultured endothelial cells [12]. Our previous study
found that both ECM1 and vascular endothelial growth
factor-C (VEGF-C) have a synergistic effect on lymphan-
giogenesis, so as to facilitate lymphatic metastasis of
breast cancer [13]. However, whether ECM1 correlates to
carcinogenesis and metastasis of gastric cancer has not yet
been clarified.
Therefore, we have attempted to determine the rela-
tionship between ECM1 expression, LMVD, and the
clinicopathological parameters in gastric cancer patients
to further discuss the clinical significance of ECM1 in
carcinogenesis and lymphatic metastasis of human gas-
tric cancer.Methods
Patients and specimens
The research protocol was approved by the Ethics
Committee of Human Experimentation in our country
and was performed in accordance with the principles of
the Declaration of Helsinki. All specimens were obtained
from patients who had undergone gastrectomy at our
cancer center between 2009 and 2010. Primary tumor
specimen and the matched non-cancerous mucosal tis-
sue (located more than 5 cm away from tumor margins)
were collected. All diagnosis has been confirmed by
pathology. Metastatic tumor specimen from other
tissue origins or from patients underwent neoadjuvantFigure 1 Immunohistochemical labeling of lymphatic microvessels (En
noncancerous gastric tissue. (A-D) Lymphatic microvessels labeled with
lymphatic vessels were large, within which was nests of no staining tumor
collapsed lumen, with irregular cell walls (long arrow). (C) Invaded muscle tiss
as ‘lymphatic vessel invasion’ (asterisks). (D) Non-cancerous mucosa (×200). Lo
blood capillaries. Asterisks represented the areas where tumor cells are. (E) LM
non-cancerous counterparts (N) (*** P <0.001).chemotherapy or radiotherapy was excluded. Written
informed consents were obtained from all patients.
Real-time PCR (RT-PCR)
Specimens were frozen immediately in liquid nitrogen
after being isolated. Total RNA was extracted from the
frozen tissues using Trizol reagent according to the
manufacturer’s instruction (Invitrogen, USA). Reverse
transcription of total RNA into cDNA was conducted
using TaKaRa Reverse Transcription Reagents (TaKaRa
Bio, Japan) at 37°C for 15 min, followed by 85°C for 5 s.
Primers were designed using Primer Premier 5.0 soft-
ware (Premier, Canada) and synthesized by Invitrogen,
USA. Each reaction was performed in triplicate. The
oligonucleotide primers were as follows: ECM1 mRNA
sequence-specific primers (GenBank: NM 004425.3)
were forward: 5′-CAAATCTGCCTTCCTAACCG-3′ and
reverse: 5′-AAGCAGGAGAACCGAGCC-3′; GAPDH
mRNA was used as an internal standard. Its mRNA
sequence-specific primers (GenBank: NM 002046.3)
were forward: 5′-GAAGGTGAAGGTCGGAGTC-3′ and
reverse: 5′-GAAGATGGTGATGGGATTTC-3′. Real-time
quantitative PCR was performed using the TaKaRa SYBRR®
Premix Ex Taq™ II PCR kit (TaKaRa Bio, Japan) in a Roche
Lightcycler 480 instrument (Roche, Switzerland). Reactions
were performed in 10 μL volumes with denaturation at
95°C for 5 s, annealing at 58°C for 15 s, and extension at
72°C for 20 s, over 45 cycles. Semi-quantitative analysis
was conducted by averaging the triplicates of the cycle
threshold (Ct) for the target genes and dividing theVision™) and LMVD in primary gastric cancer tissue and
D2-40 by IHC (EnVision™). (A, B) Gastric cancer (×100), (A) peritumoral
cells (asterisks); (B) intratumoral lymphatic vessels had narrow and
ue (×200). There were a few tumor cells in dilated lymphatic microvessels,
ng arrows indicated lymphatic microvessels, and short arrows denoted
VD in gastric cancer tissue (T) was statistically higher than that in the
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same specimen.Immunohistochemistry staining and evaluation
Briefly, 4 μm consecutive sections of formalin-fixed,
paraffin-embedded tissues were deparaffinized, stepwise
rehydrated, and the endogenous peroxide blocked. Before
staining, slides were performed using microwave antigen
retrieval, and then incubated with anti-ECM1 antibody
(clone SC-05, Abcam, UK; 1:20 dilution) and D2-40 anti-
body (clone D2-40, Abcam, UK; 1:40 dilution), respect-
ively. Non-specific binding was blocked by using 10%
non-immune serum (Santa Cruz, CA, USA.) for 10 min
prior to antibody incubation. After rinsing, slides were
incubated with EnVision™ Detection Systems (Dako,
Denmark), counterstained with hematoxylin, dehydrated,
and mounted. Negative controls were processed using the
same procedure, except that 10% non-immune mouse






Male 47 13 34
Female 30 10 20
Age (years)
<60 37 10 27
≥60 40 13 27
Differentiation degree
Low 36 11 25
Moderate 23 5 18
Well 18 7 11
Depth of invasion
T1-T2 23 18 5
T3-T4 54 5 49
Lymph node metastasis
0 34 9 25
1-2 18 9 11
3-6 10 3 7
≥7 15 4 11
TNM stage
0-I 21 12 9
II-III 27 11 45
‘+’, ‘++’, and ‘+++’ for ECM1 IHC staining are grouped together as ‘+’.
T1: lamina propria and submucosa; T2: muscularis propria and subserosa; T3: expos
**P <0.01.
***P <0.001.
P <0.05 is considered statistically significant.primary antibodies. All sections were also stained by
hematoxylin and eosin (H&E) to confirm their histological
diagnosis and other microscopic characteristics. Tumor
size, depth of invasion, and lymph node metastasis were
determined by pathology.
Morphometric analyses and staining scores were esti-
mated independently by two observers who had no prior
knowledge of the patients’ clinicopathologic data. As
previously reported [7], a modified Weidner’s method
was employed to calculate lymphatic microvessel density
(LMVD). It was assessed by counting the number of im-
munostained vessels with D2-40 staining on tissue sec-
tions. The area containing the most stained vessels (‘hot
spots’) was first identified by scanning the whole section
at low magnification (×40); then number of positive ves-
sels was counted in two high magnification fields (×200)
in the hot spot. LMVD in tumor sections was deter-
mined by averaging the number of total lymphatic ves-
sels in all the fields of each slide, including within the
tumor or at the periphery of the tumor. The number ofracteristics
ssion LMVD






















ure to serosa; T4: invasion into serosa.
Figure 2 Comparison of LMVD in tissues without/with lymph node metastasis. (A) LMVD in tumor specimen with lymph node metastasis
(LN+) was higher than that without lymph node metastasis (LN-), although the difference did not reach statistical significance (P >0.05). (B) LMVD
in non-cancerous gastric mucosa from patients with lymph node metastasis (LN+) was statistically higher than that without metastasis (LN-)
(** P <0.01).
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age of four counts (two authors and two microscopic
fields). If there was any discrepancy of more than 10% of
the microvessel count, these discordant sections were
recounted until reaching consensus. ECM1 expression
was judged according to the methods previously de-
scribed [14]: the percentage of positive staining = (the
numbers of positive samples/the numbers of samples
tested) × 100%.
Statistical analysis
SPSS (Chicago, IL, USA) software was employed. Data
which were normally distributed were expressed as
mean ± standard error of the mean (S.E.M.). StatisticalFigure 3 Melting curves of GAPDH and ECM1 real-time fluorescent qu
ECM1 is 88.3°C).evaluation was performed using Spearman correlation
test to analyze the rank data and Mann–Whitney U-test
to differentiate non-parametric means of different groups.
Chi-square test, Yates’ correction, or Fisher’s exact test
was used to analyze qualitative independent variables. All
statistical tests were two-side. A P value of less than 0.05
was considered as statistically significant.
Results
LMVD counting
D2-40 is a highly specific marker for lymphatic endothe-
lium and has been proven valuable in distinguishing
lymph vessels from blood vessels [15-17]. Microscopic-
ally, immunostained lymphatic vessels were lined with aantitative PCR products (Tm of GAPDH is 85.05°C, while that of
Table 2 ECM1 expression in gastric cancer specimen and non-cancerous counterparts




Staining grades of ECM1 χ2
- + ++ +++
Tumor specimen 0.010 ± 0.002 70.1(54/77) 23 35 13 6
Non-cancerous mucosa 0.007 ± 0.002 7.48** 7.8(6/77) 71 5 1 0 62.91***
**P <0.01.
***P <0.001.
P <0.05 is considered statistically significant.
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vessels showed negative staining (Figure 1A-D). LMVD
in gastric cancer tissue from 77 patients was 7.79 ± 0.88
lymphatic microvessels per × 200 field (LMV per × 200
field). While in the non-cancerous counterparts, LMVD
was 2.65 ± 0.38 LMV per × 200 field. The difference in
LMVD between these two tissue types was statistically
significant (Mann–Whitney test, P <0.001) (Figure 1E).
As shown in Table 1, there was no statistical difference
of LMVD among groups of different gender, age at diag-
nosis, differentiation degree, and depth of tumor inva-
sion, lymph node metastasis or TNM stage (P >0.05,
respectively). In addition, though the difference was not
statistically significant (Mann–Whitney test, P = 0.065),
LMVD in the tumor specimen with lymphatic metastasis
(9.02 ± 1.16 LMV per × 200 field) tended to be higher
than that without lymph node metastasis (6.74 ± 1.29
LMV per × 200 field) (Figure 2A). And LMVD inFigure 4 Representative IHC staining of ECM1 (EnVision™, ×100). (A) a
(E) ++ for ECM1 staining, (F) +++ for ECM1 staining. Asterisks represent th
(C, D) gastric cancer, (E, F) metastatic lymph node.paracancerous gastric mucosa with lymph node metas-
tasis (3.66 ± 0.70 LMV per × 200 field) was statistically
higher than that without metastasis (1.79 ± 0.34
LMV per × 200 field; Mann–Whitney test, P = 0.008)
(Figure 2B).
ECM1 expression
The corresponding melting curves of PCR products were
shown in Figure 3. The mean normalized expression
level of ECM1 mRNA in tumor specimen was statisti-
cally higher than that in non-cancerous counterparts
(Mann–Whitney test, P <0.01; Table 2). ECM1 protein
was specifically expressed in the cytoplasm of tumor cells,
with scattered expression in cell membrane (Figure 4);
whereas, the nucleus had no staining. Notably, the protein
was also detected in the cytoplasm of metastatic cells in
invaded tissue and lymph node (Figure 4E, F). The differ-
ence in the rate of ECM1 expression between tumor tissuend (C) negative for ECM1 staining, (B) and (D) + for ECM1 staining,
e areas where tumor cells are. (A, B) non-cancerous gastric mucosa,
Figure 5 Correlation of LMVD and ECM1 expression in gastric cancer (EnVision™, ×100). (A, B) lymphatic microvessels labelled by D2-40,
(C) +/- for ECM1 staining, (D) +++ for ECM1 staining. (A, C) & (B, D) represent the matched specimen from the same patient, respectively.
Asterisks represent the areas where tumor cells are. (E) LMVD in gastric cancer with ECM1 positive staining (ECM1+) was statistically higher than
that without ECM1 staining (ECM1-) (* P <0.05).
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7.8%) was statistically different (χ2 = 62.91, P <0.001;
Table 2). As shown in Table 1, the protein expression of
ECM1 in tumor specimen was correlated with depth
of tumor invasion and TNM stage (Fisher’s exact test,
P <0.001 and P = 0.002, respectively). However, correlation
of ECM1 expression with other clinicopathologic char-
acteristics was not significant, including patients’ gen-
der, age at diagnosis, differentiation degree, or lymph
nodes metastasis (P >0.05, respectively). And ECM1 ex-
pression rate in tumor specimen with lymph node me-
tastasis (25/34, 73.5%) was not statistically higher than
that without lymph node metastasis (29/43, 67.4%)
(Fisher’s exact test, P = 0.623).
ECM1 expression and LMVD
As representative shown in Figure 5, tumor sections
which were ECM1-positive staining had elevated LMVD
(Mann–Whitney test, P = 0.014). A positive correlation
was further established between ECM1 expression and
LMVD in gastric cancer tissue (Spearman’s R = 0.407,
P = 0.001; Table 3).Table 3 ECM1 expression and LMVD (LMV per x 200 field) in
Tissue type ECM1 immunostain
-
Tumor specimen (23/77) 4.47 ± 0.95
Non-cancerous mucosa (71/77) 2.71 ± 0.41
‘+’, ‘++’, and ‘+++’ for ECM1 IHC staining are all grouped together as ‘+’.
**P <0.01 is considered statistically significant.Discussion
Lymphangiogenesis plays an essential part in carcino-
genesis and metastasis of malignancies, as newly born
lymph microvessels are the direct access to lymph nodes
and distant spread. Our present study showed that, com-
pared to the non-cancerous counterparts, the number of
lymphatic microvessels obviously increased in gastric
cancer. Lymphatic microvessels are well-known to be a
discontinuous basement membrane and lack tight inter-
endothelial junctions. Therefore, it is believed that these
vessels would be convenient for tumor cells to pass
through. It is meant that, tumor-induced lymphangio-
genesis provides more opportunity for tumor cells to the
lymphatic system and even distant dissemination [4,5,18].
As a tumor-derived protein, ECM1 was previously re-
ported to be over-expressed in various malignant epithelial
tumors, and tumors with lymph node metastases were
more likely to be ECM1-positive [13,19,20]; although the
exact role of this protein was still controversial. It was
known that tumor-induced lymphangiogenesis was prior
to the onset of lymphatic metastasis in lymph node and
distant spread [1-3]. In the present study, that ECM1gastric cancer and non-cancerous counterparts
ing Spearman R P
+
(54/77) 9.22 ± 1.13 0.407 0.001**
(6/77) 2.00 ± 1.05 -0.061 0.633
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number of lymph microvessels in tumor specimen suggest
the potential value of this protein in predicting lymphatic
metastasis of gastric cancer. Since ECM1 plays a vital role
in the promotion for endothelial cells proliferation [12]
and lymphangiogenesis [13], we presumed that the protein
might involve in lymphangiogenesis participating in the
metastatic progression of gastric cancer. Moreover, the
same as in the primary tumor, ECM1 was also expressed
in metastatic cells of invaded tissues, indicating that the
protein was correlated with metastatic potential of tumor
cells. Would this provide a clue of the prediction of ECM1
in carcinogenesis and metastasis of gastric cancer? Of
course, further studies are still needed to further determine.
Compared to the non-cancerous counterparts, both
mRNA and protein expression of ECM1 were elevated
in gastric cancer tissue. Moreover, the protein was posi-
tively correlated with depth of tumor invasion and TNM
stage. Though a previous study showed that the level of
ECM1 mRNA expression was higher in TNM stage I
thyroid cancers than in stage II and III tumors [20]. Our
results are consistent with the ECM1 expression status
observed in hepatocellular cancer [19] and suggest that
ECM1 expression correlates to carcinogenesis and inva-
siveness of tumor cells. Different specimens from variant
tissues and relative small sample size may cause incon-
sistencies in the results obtained from these studies. It
was also reported that ECM1 could be an important
prognostic marker in patients with breast cancer [21] or
with hepatocellular cancer [19], which indicated that de-
tecting abnormal expression of this protein would be use-
ful to predict an unfavorable prognosis in malignancy.
Conclusions
In summary, ECM1 expression is aberrant elevated in
gastric cancer and is positively correlated with LMVD
and several clinicopathological characteristics, as is depth
of tumor invasion and TNM stage; thus providing a clue
that evaluation of ECM1 expression in gastric cancer tis-
sues facilitates the prediction of carcinogenesis and meta-
static spread in human gastric cancer. We hope that this
report would facilitate to manage the disease and benefit
the patients in clinical practice.
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